secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)
CIK:        0001335105
Form:       8-K
Filed at:   2024-07-12T23:59:59+00:00
Accession:  0001493152-24-027085
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Lixte terminates City of Hope trial agreement for LB-100 Phase 1b; seeks new sites
--------------------------------------------------------------------------------

- Terminated Clinical Research Support Agreement with City of Hope effective July 8, 2024.
- Agreement covered Phase 1b trial of LB-100 combined with Carboplatin/Etoposide/Atezolizumab for extensive-stage small cell lung cancer.
- Company plans to explore alternative clinical trial sites to continue the study.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1335105/000149315224027085/0001493152-24-027085-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1335105/000149315224027085/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-027085

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer